PT92024B - Processo para a purificacao da estreptoquinase de proteinas contaminadoras - Google Patents

Processo para a purificacao da estreptoquinase de proteinas contaminadoras Download PDF

Info

Publication number: PT92024B
Authority: PT; Portugal
Prior art keywords: streptokinase; mixture; process according; reagent; contaminating proteins
Prior art date: 1988-10-19

Application number

PT92024A

Other languages

English (en)

Portuguese (pt)

Other versions

PT92024A (pt

Inventor

Christopher Joseph Mannix

Richard Anthony Godwin Smith

Ceri John Lewis

Julian Stanley Harber

Original Assignee

Beecham Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-19

Filing date

1989-10-18

Publication date

1995-08-09

1989-10-18 Application filed by Beecham Group Ltd filed Critical Beecham Group Ltd

1990-04-30 Publication of PT92024A publication Critical patent/PT92024A/pt

1995-08-09 Publication of PT92024B publication Critical patent/PT92024B/pt

Links

238000000034 method Methods 0.000 title claims abstract description 53
108090000623 proteins and genes Proteins 0.000 title claims abstract description 33
102000004169 proteins and genes Human genes 0.000 title claims abstract description 33
238000000746 purification Methods 0.000 title description 8
229920000642 polymer Polymers 0.000 title 1
108010023197 Streptokinase Proteins 0.000 claims abstract description 43
229960005202 streptokinase Drugs 0.000 claims abstract description 42
239000000203 mixture Substances 0.000 claims abstract description 27
239000011159 matrix material Substances 0.000 claims abstract description 24
239000003153 chemical reaction reagent Substances 0.000 claims abstract description 20
125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 19
238000000926 separation method Methods 0.000 claims abstract description 8
239000003638 chemical reducing agent Substances 0.000 claims abstract description 7
238000004587 chromatography analysis Methods 0.000 claims description 11
-1 5-carboxy-2-pyridylthio 2-pyridylthio 4-pyridylthio Chemical group 0.000 claims description 6
238000006243 chemical reaction Methods 0.000 claims description 5
230000000717 retained effect Effects 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 5
239000000356 contaminant Substances 0.000 claims description 3
150000001204 N-oxides Chemical class 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
229910052744 lithium Inorganic materials 0.000 claims 1
230000036647 reaction Effects 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 21
150000003573 thiols Chemical class 0.000 description 16
239000000872 buffer Substances 0.000 description 12
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 11
HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 9
239000000463 material Substances 0.000 description 9
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
239000012460 protein solution Substances 0.000 description 8
229920000936 Agarose Polymers 0.000 description 7
238000001556 precipitation Methods 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000001914 filtration Methods 0.000 description 6
239000002244 precipitate Substances 0.000 description 5
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
108010024636 Glutathione Proteins 0.000 description 4
229960003180 glutathione Drugs 0.000 description 4
239000012535 impurity Substances 0.000 description 4
238000002203 pretreatment Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 3
108010011834 Streptolysins Proteins 0.000 description 3
235000010633 broth Nutrition 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000003527 fibrinolytic agent Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
125000004149 thio group Chemical group *S* 0.000 description 3
229960000103 thrombolytic agent Drugs 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
229920001410 Microfiber Polymers 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000012062 aqueous buffer Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
150000002019 disulfides Chemical class 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000003658 microfiber Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
108010058207 Anistreplase Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
102000013566 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
241000194048 Streptococcus equi Species 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
108010045649 agarase Proteins 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
150000007942 carboxylates Chemical group 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000011152 fibreglass Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000010399 physical interaction Effects 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
238000011045 prefiltration Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000010992 reflux Methods 0.000 description 1
239000012898 sample dilution Substances 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
239000012209 synthetic fiber Substances 0.000 description 1
FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3153—Streptokinase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/814—Enzyme separation or purification
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/814—Enzyme separation or purification
- Y10S435/815—Enzyme separation or purification by sorption
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/885—Streptococcus

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Iron Core Of Rotating Electric Machines (AREA)
Glass Compositions (AREA)
Removal Of Specific Substances (AREA)
Steroid Compounds (AREA)

PT92024A 1988-10-19 1989-10-18 Processo para a purificacao da estreptoquinase de proteinas contaminadoras PT92024B (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB888824496A GB8824496D0 (en)	1988-10-19	1988-10-19	Process

Publications (2)

Publication Number	Publication Date
PT92024A PT92024A (pt)	1990-04-30
PT92024B true PT92024B (pt)	1995-08-09

Family

ID=10645453

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT92024A PT92024B (pt)	1988-10-19	1989-10-18	Processo para a purificacao da estreptoquinase de proteinas contaminadoras

Country Status (15)

Country	Link
US (1)	US5334384A (da)
EP (1)	EP0365278B1 (da)
JP (1)	JP2837467B2 (da)
KR (1)	KR0136613B1 (da)
AT (1)	ATE103633T1 (da)
AU (1)	AU622492B2 (da)
CA (1)	CA2000850A1 (da)
DE (1)	DE68914242T2 (da)
DK (1)	DK515889A (da)
ES (1)	ES2062029T3 (da)
GB (1)	GB8824496D0 (da)
IE (1)	IE63478B1 (da)
NZ (1)	NZ231039A (da)
PT (1)	PT92024B (da)
ZA (1)	ZA897849B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE513042T1 (de)	1998-02-05	2011-07-15	Glaxosmithkline Biolog Sa	Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
US6388073B1 (en)	2000-07-26	2002-05-14	Shire Us Inc.	Method for the manufacture of anagrelide
WO2002030542A2 (en)	2000-10-12	2002-04-18	Robert Corcoran	Purification of substance by reaction affinity chromatography
KR20020007231A (ko) *	2001-08-01	2002-01-26	이병철	스트렙토키나제의 정제방법
US20060030574A1 (en) *	2004-08-04	2006-02-09	Shire Holdings Ag	Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US7700608B2 (en) *	2004-08-04	2010-04-20	Shire Holdings Ag	Quinazoline derivatives and their use in the treatment of thrombocythemia
US7910597B2 (en) *	2006-11-28	2011-03-22	Shire Llc	Substituted quinazolines
US8304420B2 (en)	2006-11-28	2012-11-06	Shire Llc	Substituted quinazolines for reducing platelet count
NZ589557A (en) *	2008-06-04	2012-08-31	Talecris Biotherapeutics Inc	Immobilised streptokinase, method and kit for preparing plasmin
HUE025670T2 (en)	2009-03-03	2016-04-28	Grifols Therapeutics Inc	A method for producing plasminogen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2784145A (en) *	1955-11-22	1957-03-05	American Cyanamid Co	Recovery of streptokinase
US3419472A (en) *	1960-10-24	1968-12-31	American Cyanamid Co	Process for preparing streptokinaserich material
US3226304A (en) *	1960-10-24	1965-12-28	American Cyanamid Co	High purity streptokinase and process for preparing same
US3255094A (en) *	1963-01-10	1966-06-07	Baxter Laboratories Inc	Method for purification of streptokinase
US3444045A (en) *	1966-09-20	1969-05-13	American Cyanamid Co	Process for purifying streptokinase
US4381346A (en) *	1979-11-13	1983-04-26	Huasin Syed S	Isolation of plasminogen activators useful as therapeutic and diagnostic agents

1988
- 1988-10-19 GB GB888824496A patent/GB8824496D0/en active Pending
1989
- 1989-10-17 DK DK515889A patent/DK515889A/da not_active Application Discontinuation
- 1989-10-17 NZ NZ231039A patent/NZ231039A/en unknown
- 1989-10-17 US US07/422,430 patent/US5334384A/en not_active Expired - Lifetime
- 1989-10-17 IE IE333889A patent/IE63478B1/en not_active IP Right Cessation
- 1989-10-17 DE DE68914242T patent/DE68914242T2/de not_active Expired - Fee Related
- 1989-10-17 ZA ZA897849A patent/ZA897849B/xx unknown
- 1989-10-17 ES ES89310648T patent/ES2062029T3/es not_active Expired - Lifetime
- 1989-10-17 AT AT89310648T patent/ATE103633T1/de not_active IP Right Cessation
- 1989-10-17 AU AU42964/89A patent/AU622492B2/en not_active Ceased
- 1989-10-17 CA CA002000850A patent/CA2000850A1/en not_active Abandoned
- 1989-10-17 EP EP89310648A patent/EP0365278B1/en not_active Expired - Lifetime
- 1989-10-18 PT PT92024A patent/PT92024B/pt not_active IP Right Cessation
- 1989-10-18 JP JP1269272A patent/JP2837467B2/ja not_active Expired - Lifetime
- 1989-10-18 KR KR1019890015025A patent/KR0136613B1/ko not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DK515889A (da)	1990-04-20
DE68914242T2 (de)	1994-07-07
US5334384A (en)	1994-08-02
EP0365278B1 (en)	1994-03-30
DK515889D0 (da)	1989-10-17
JP2837467B2 (ja)	1998-12-16
AU622492B2 (en)	1992-04-09
KR900006512A (ko)	1990-05-08
JPH02128688A (ja)	1990-05-17
PT92024A (pt)	1990-04-30
NZ231039A (en)	1991-07-26
EP0365278A2 (en)	1990-04-25
ES2062029T3 (es)	1994-12-16
AU4296489A (en)	1990-04-26
IE63478B1 (en)	1995-04-19
IE893338L (en)	1990-04-19
EP0365278A3 (en)	1991-08-28
GB8824496D0 (en)	1988-11-23
ATE103633T1 (de)	1994-04-15
KR0136613B1 (ko)	1998-04-25
CA2000850A1 (en)	1990-04-19
ZA897849B (en)	1990-10-31
DE68914242D1 (de)	1994-05-05

Legal Events

Date

Code

Title

Description

1995-08-09

FG3A

Patent granted, date of granting

Effective date: 19950404

1998-05-29

PC3A

Transfer or assignment

Free format text: 980213 ROBERTS LABORATORIES INC. US

2001-02-28

MM3A

Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20001031

Publication	Publication Date	Title
US4075193A (en)	1978-02-21	Process for producing intravenous immune globulin
CA1339389C (en)	1997-08-26	Purified protein a compositions and methods for their preparation
EP0365278B1 (en)	1994-03-30	Protein purification process
Hranitzky et al.	1980	Characterization of a flagellar sheath protein of Vibrio cholerae
JPH04295432A (ja)	1992-10-20	血液凝固ｉｘ因子を含有する複合体
JPS6348515B2 (da)	1988-09-29
Sakamoto et al.	1975	Studies on the interaction between heparin and mouse bone collagenase
Tsuboi et al.	1954	Acid phosphatase. II. Purification of human red cell phosphomonoesterase
JPS5832591B2 (ja)	1983-07-14	ウロキナ−ゼの精製法
US5304636A (en)	1994-04-19	Receptor for the human rhinovirus minor group
US3976767A (en)	1976-08-24	Purification of hepatitis B surface antigen by chromatography on agarose containing aminoalkyl residues
JPH03501085A (ja)	1991-03-14	化学的プロセス
JP3148895B2 (ja)	2001-03-26	精製方法
EP0110688B1 (en)	1990-02-28	Angiogenic factor production
IL86077A (en)	1994-02-27	Receptor of the small rhinovirus receptor group its preparation and pharmaceutical compositions containing it
EP0203865B1 (fr)	1992-03-25	Procédé de séparation des anticorps antifacteur VIII:C, utilisable notamment pour l'épuration du plasma sanguin d'un hemophile de type A.
US5445958A (en)	1995-08-29	Process for purifying blood clotting factors
Yeltman et al.	1977	Purification and characterization of aldolase from human erythrocytes
US5723325A (en)	1998-03-03	Indolyl-3-alkane alpha-hydroxylase compositions from pseudomonas XA
EP0310719B1 (en)	1992-05-13	Method for purification of antibodies
WO1995004077A1 (en)	1995-02-09	Method of purifying plasminogen
US3444045A (en)	1969-05-13	Process for purifying streptokinase
JP2627186B2 (ja)	1997-07-02	レトロウイルスの精製方法
Singh et al.	1982	Biological effects of slate dust: solubility and hemolytic studies
EP0868507A1 (en)	1998-10-07	Process for the purification of urease from helicobacter pylori